Get Free Demat Account*
Open Your Free Demat Account
Enjoy low brokerage on delivery trades
By Dalal Street Investment Journal (DSIJ)
A quality issue linked to the API used in semaglutide delayed commercial supplies, sending Dr Reddy Laboratories shares down more than 5% to ₹1,279.80. The company said patient safety and global regulatory filings remain unaffected and is investigating the root cause while taking corrective measures.
Dr Reddy Laboratories came into the spotlight and fell more than 5% in the early trade on Thursday. This comes after the company informed exchanges regarding a delay in the commercial availability of some batches of its semaglutide drug. The news impacted investor sentiment, which in turn caused the stock price to fall.
Importantly, this comes at a time when semaglutide has become an important drug in the pharmaceutical industry, both globally and in India. The drug has seen a lot of demand over the last few years, particularly since its patent expired, making way for generic companies.
The company revealed that some of the batches of the semaglutide drug were not meeting the quality specifications owing to an API-related issue.
The company added that it is investigating the root cause and has started taking corrective measures to address the quality issue. Commercial supplies will remain suspended until the manufacturing deviation is thoroughly resolved.
The company also clarified that the issue does not affect patient safety. It further said there is no impact on the product's existing global regulatory filings.
company remains committed to ensuring reliable global supplies of the metabolic therapy.
To address investor queries, the management has scheduled a conference call on July 9, 2026, between 4:30 pm and 5:00 pm IST.
Dr Reddy Laboratories Ltd was established in 1984 by Dr K. Anji Reddy and his associates. The Hyderabad-based pharmaceutical company is a vertically integrated manufacturer of formulations and pharmaceutical products.
It has a diversified manufacturing footprint across India, the US, the UK, China and Mexico. The company operates in several therapeutic segments and has a strong presence in both domestic and international markets.
Its share price traded at ₹1,279.80 at around 11:06 am IST on July 9, 2026. The stock was down ₹69.20, or 5.13%, from its previous closing price of ₹1,349.00.
The stock opened at ₹1,340.00, lower than its previous close, indicating weak sentiment right from the opening bell. Selling pressure continued during the session as investors reacted to the company's latest disclosure.
The stock's longer-term performance has also remained muted. On a year-to-date basis, it has declined by more than 2.5%. Over the past year, the stock has delivered a gain of just over 1%.
Source: Dalal Street Investment Journal, NSE
SEBI Registered Research Analyst (INH000006396).
Founded in 1986, Dalal Street Investment Journal (DSIJ) brings decades of experience in India’s equity markets. DSIJ's research combines fundamental analysis with price action, guided by disciplined risk management and capital preservation. They follow a structured, data-driven approach designed to help investors and traders make informed decisions beyond short-term market noise.
Disclaimer :
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Content Partner - Dalal Street Investment Journal Wealth Advisory Private Limited
This article is for educational purposes only and should not be considered investment advice. Market investments are subject to risks. DSIJ Wealth Advisory Private Limited is a SEBI-registered Research Analyst (Reg. No: INH000006396) and Investment Adviser (Reg. No: INA000001142). Please consult your financial adviser before investing.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading